ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.57% | 68.43% | -165.09% | 17.71% | -15.91% |
| Total Depreciation and Amortization | -7.15% | -72.51% | -13.77% | 7.43% | 1.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.10% | -89.51% | 1,472.67% | -31.11% | 20.52% |
| Change in Net Operating Assets | -10.82% | 122.33% | 827.51% | -104.12% | 1,280.78% |
| Cash from Operations | 11.52% | 27.63% | 24.49% | -29.81% | 28.52% |
| Capital Expenditure | -- | -- | 78.46% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 78.46% | -135.91% | -- |
| Total Debt Issued | -24.53% | 120.15% | -60.61% | 1,550.00% | -94.29% |
| Total Debt Repaid | 85.16% | -56.57% | -98.00% | 43.82% | 43.67% |
| Issuance of Common Stock | -- | -- | -36.89% | -59.58% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.90% | -28.97% | -23.70% | 28.57% | 18.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 171.46% | 9.91% | 36.16% | -91.22% | 91.29% |